AUTL
Autolus Accelerates Commercialization and Expands Product Portfolio
The biopharmaceutical company Autolus has recently reported its fourth quarter 2025 and full year 2025 financial results, showcasing significant advancements in commercialization and product development. During the conference call on March 27, 2026, CEO Dr. Christian Itin highlighted the successful launch of AUCATZYL in the U.S., with $74.3